These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial. Zinsou JF; Diemert DJ; Dejon-Agobé JC; Adégbité BR; Honkpehedji YJ; Vodonou KG; Bikangui R; Edoa JR; Massinga Loembe M; Li G; Yazdanbakhsh M; Bottazzi ME; van Leeuwen R; Kremsner PG; Hotez PJ; Bethony JM; Grobusch MP; Adegnika AA Lancet Infect Dis; 2024 Jul; 24(7):760-774. PubMed ID: 38513684 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial. Adegnika AA; de Vries SG; Zinsou FJ; Honkepehedji YJ; Dejon Agobé JC; Vodonou KG; Bikangui R; Bouyoukou Hounkpatin A; Bache EB; Massinga Loembe M; van Leeuwen R; Molemans M; Kremsner PG; Yazdanbakhsh M; Hotez PJ; Bottazzi ME; Li G; Bethony JM; Diemert DJ; Grobusch MP; Lancet Infect Dis; 2021 Feb; 21(2):275-285. PubMed ID: 32926834 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults. Diemert DJ; Freire J; Valente V; Fraga CG; Talles F; Grahek S; Campbell D; Jariwala A; Periago MV; Enk M; Gazzinelli MF; Bottazzi ME; Hamilton R; Brelsford J; Yakovleva A; Li G; Peng J; Correa-Oliveira R; Hotez P; Bethony J PLoS Negl Trop Dis; 2017 May; 11(5):e0005574. PubMed ID: 28464026 [TBL] [Abstract][Full Text] [Related]
5. New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74. Pearson MS; Jariwala AR; Abbenante G; Plieskatt J; Wilson D; Bottazzi ME; Hotez PJ; Keegan B; Bethony JM; Loukas A Hum Vaccin Immunother; 2015; 11(5):1251-7. PubMed ID: 26018444 [TBL] [Abstract][Full Text] [Related]
6. Optimization and revision of the production process of the Necator americanus glutathione S-transferase 1 (Na-GST-1), the lead hookworm vaccine recombinant protein candidate. Curti E; Seid CA; Hudspeth E; Center L; Rezende W; Pollet J; Kwityn C; Hammond M; Matsunami RK; Engler DA; Hotez PJ; Elena Bottazzi M Hum Vaccin Immunother; 2014; 10(7):1914-25. PubMed ID: 25424799 [TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of the Na-APR-1 hookworm vaccine in infection-naïve adults. Diemert DJ; Zumer M; Campbell D; Grahek S; Li G; Peng J; Elena Bottazzi M; Hotez P; Bethony J Vaccine; 2022 Oct; 40(42):6084-6092. PubMed ID: 36114129 [TBL] [Abstract][Full Text] [Related]
14. An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection. Pearson MS; Bethony JM; Pickering DA; de Oliveira LM; Jariwala A; Santiago H; Miles AP; Zhan B; Jiang D; Ranjit N; Mulvenna J; Tribolet L; Plieskatt J; Smith T; Bottazzi ME; Jones K; Keegan B; Hotez PJ; Loukas A FASEB J; 2009 Sep; 23(9):3007-19. PubMed ID: 19380510 [TBL] [Abstract][Full Text] [Related]
15. Development of a peptide vaccine against hookworm infection: Immunogenicity, efficacy, and immune correlates of protection. Shalash AO; Becker L; Yang J; Giacomin P; Pearson M; Hussein WM; Loukas A; Toth I; Skwarczynski M J Allergy Clin Immunol; 2022 Jul; 150(1):157-169.e10. PubMed ID: 35278494 [TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies to the hookworm hemoglobinase Na-APR-1: implications for a multivalent vaccine against hookworm infection and schistosomiasis. Pearson MS; Pickering DA; Tribolet L; Cooper L; Mulvenna J; Oliveira LM; Bethony JM; Hotez PJ; Loukas A J Infect Dis; 2010 May; 201(10):1561-9. PubMed ID: 20367477 [TBL] [Abstract][Full Text] [Related]
17. Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine. Seid CA; Curti E; Jones RM; Hudspeth E; Rezende W; Pollet J; Center L; Versteeg L; Pritchard S; Musiychuk K; Yusibov V; Hotez PJ; Bottazzi ME Hum Vaccin Immunother; 2015; 11(6):1474-88. PubMed ID: 25905574 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of the hookworm Na-ASP-2 vaccine candidate: characterization of humoral and cellular responses after vaccination in the Sprague Dawley rat. Fujiwara RT; Bethony J; Bueno LL; Wang Y; Ahn SY; Samuel A; Bottazzi ME; Hotez P; Mendez S Hum Vaccin; 2005; 1(3):123-8. PubMed ID: 17012856 [TBL] [Abstract][Full Text] [Related]
19. Model for product development of vaccines against neglected tropical diseases: a vaccine against human hookworm. Bottazzi ME; Brown AS Expert Rev Vaccines; 2008 Dec; 7(10):1481-92. PubMed ID: 19053205 [TBL] [Abstract][Full Text] [Related]
20. Advances in vaccines against neglected tropical diseases: enhancing physical stability of a recombinant hookworm vaccine through biophysical and formulation studies. Plieskatt JL; Rezende WC; Olsen CM; Trefethen JM; Joshi SB; Middaugh CR; Hotez PJ; Bottazzi ME Hum Vaccin Immunother; 2012 Jun; 8(6):765-76. PubMed ID: 22495115 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]